(Total Views: 941)
Posted On: 11/05/2020 6:46:31 AM
Post# of 154981
Humanigen Signs Licensing Deal for Lenzilumab in Asia-Pacific for COVID-19
11/3/20, 11:11 AM
11:11 AM EST, 11/03/2020 (MT Newswires) -- Humanigen (HGEN) said Tuesday that it signed its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical and KPM Tech for the development and commercialization rights to lenzilumab for COVID-19 in South Korea and the Philippines.
Telcon and KPM Tech recently invested in a Humanigen offering in June.
Under the agreement, Humanigen will receive payments of up to $20 million with $6 million as an upfront payment upon execution of the licensing agreement and the balance of $14 million in two payments based on Humanigen's achievement of certain milestones in the US.
Telcon and KPM Tech will take care of gaining regulatory approval and commercializing lenzilumab.
Shares of Humanigen were up nearly 2% in recent trading.
Price: 10.96, Change: +0.20, Percent Change: +1.86
11/3/20, 11:11 AM
11:11 AM EST, 11/03/2020 (MT Newswires) -- Humanigen (HGEN) said Tuesday that it signed its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical and KPM Tech for the development and commercialization rights to lenzilumab for COVID-19 in South Korea and the Philippines.
Telcon and KPM Tech recently invested in a Humanigen offering in June.
Under the agreement, Humanigen will receive payments of up to $20 million with $6 million as an upfront payment upon execution of the licensing agreement and the balance of $14 million in two payments based on Humanigen's achievement of certain milestones in the US.
Telcon and KPM Tech will take care of gaining regulatory approval and commercializing lenzilumab.
Shares of Humanigen were up nearly 2% in recent trading.
Price: 10.96, Change: +0.20, Percent Change: +1.86
(0)
(0)
